Cargando…

The Somatostatin Analogue Octreotide Inhibits Growth of Small Intestine Neuroendocrine Tumour Cells

Octreotide is a widely used synthetic somatostatin analogue that significantly improves the management of neuroendocrine tumours (NETs). Octreotide acts through somatostatin receptors (SSTRs). However, the molecular mechanisms leading to successful disease control or symptom management, especially w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Su-Chen, Martijn, Cécile, Cui, Tao, Essaghir, Ahmed, Luque, Raúl M., Demoulin, Jean-Baptiste, Castaño, Justo P., Öberg, Kjell, Giandomenico, Valeria
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3485222/ https://www.ncbi.nlm.nih.gov/pubmed/23119007 http://dx.doi.org/10.1371/journal.pone.0048411

Ejemplares similares

Global microRNA profiling of well-differentiated small intestinal neuroendocrine tumors
por: Li, Su-Chen, et al.
Publicado: (2013)

Somatostatin Analogs Treated Small Intestinal Neuroendocrine Tumor Patients Circulating MicroRNAs
por: Li, Su-Chen, et al.
Publicado: (2015)

Paraneoplastic Antigen Ma2 Autoantibodies as Specific Blood Biomarkers for Detection of Early Recurrence of Small Intestine Neuroendocrine Tumors
por: Cui, Tao, et al.
Publicado: (2010)

Experimental and clinical studies with somatostatin analogue octreotide in small cell lung cancer.
por: Macaulay, V. M., et al.
Publicado: (1991)

Association between dopamine and somatostatin receptor expression and pharmacological response to somatostatin analogues in acromegaly
por: Venegas‐Moreno, Eva, et al.
Publicado: (2017)

Pulmonary neuroendocrine tumours and somatostatin receptor status: an assessment of unlicensed use of somatostatin analogues in the clinical practice
por: Kiesewetter, B., et al.
Publicado: (2022)

The presence of somatostatin receptors in malignant neuroendocrine tumor tissue predicts responsiveness to octreotide.
por: Kvols, L. K., et al.
Publicado: (1992)

Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumours, current aspects and new perspectives
por: Appetecchia, Marialuisa, et al.
Publicado: (2010)

E‐cadherin expression is associated with somatostatin analogue response in acromegaly
por: Venegas‐Moreno, Eva, et al.
Publicado: (2019)

The somatostatin analogue octreotide inhibits angiogenesis in the earliest, but not in advanced, stages of portal hypertension in rats
por: Mejias, Marc, et al.
Publicado: (2008)

Intraoperative detection of somatostatin-receptor-positive neuroendocrine tumours using indium-111-labelled DTPA-D-Phe1-octreotide.
por: Wangberg, B., et al.
Publicado: (1996)

Patient reported symptoms, coping and quality of life during somatostatin analogue treatment for metastatic small- intestinal neuroendocrine tumours
por: Sorbye, Halfdan, et al.
Publicado: (2020)

Transcriptome of GH-producing pituitary neuroendocrine tumours and models are significantly affected by somatostatin analogues
por: Saksis, Rihards, et al.
Publicado: (2023)

Comparative studies on the expression of somatostatin receptor subtypes, outcome of octreotide scintigraphy and response to octreotide treatment in patients with carcinoid tumours.
por: Nilsson, O., et al.
Publicado: (1998)

Octreotide, a Somatostatin Analogue, Fails to Inhibit Hypoxia-induced Retinal Neovascularization in the Neonatal Rat
por: Averbukh, Edward, et al.
Publicado: (2000)

Comparison of somatostatin receptor expression in patients with neuroendocrine tumours with and without somatostatin analogue treatment imaged with [(18)F]SiTATE
por: Eschbach, Ralf S., et al.
Publicado: (2023)

Radiolabeled Somatostatin Analogues for Diagnosis and Treatment of Neuroendocrine Tumors
por: Ambrosini, Valentina, et al.
Publicado: (2022)

Role of Somatostatin Signalling in Neuroendocrine Tumours
por: Rogoza, Olesja, et al.
Publicado: (2022)

Somatostatin Analogues in the Treatment of Neuroendocrine Tumors: Past, Present and Future
por: Stueven, Anna Kathrin, et al.
Publicado: (2019)

Somatostatin Receptor 2 Expression Profiles and Their Correlation with the Efficacy of Somatostatin Analogues in Gastrointestinal Neuroendocrine Tumors
por: Watanabe, Hirofumi, et al.
Publicado: (2022)

Identification of Candidate Serum Proteins for Classifying Well-Differentiated Small Intestinal Neuroendocrine Tumors
por: Darmanis, Spyros, et al.
Publicado: (2013)

Effects of somatostatin/octreotide treatment in neonates with congenital chylothorax
por: Yin, Rong, et al.
Publicado: (2017)

Casting a Wider NET: Pancreatic Exocrine Insufficiency Induced by Somatostatin Analogues among Patients with Neuroendocrine Tumours?
por: Hall, Lewis A., et al.
Publicado: (2023)

Efficacy and Safety of Everolimus plus Somatostatin Analogues in Patients with Neuroendocrine Tumors
por: Ge, Wenhao, et al.
Publicado: (2018)

Interaction between somatostatin analogues and targeted therapies in neuroendocrine tumor cells
por: Krug, Sebastian, et al.
Publicado: (2019)

Somatostatin Analogues according to Ki67 index in neuroendocrine tumours: an observational retrospective-prospective analysis from real life
por: Faggiano, Antongiulio, et al.
Publicado: (2015)

Diagnostic Value of Radiolabelled Somatostatin Analogues for Neuroendocrine Tumour Diagnosis: The Benefits and Drawbacks of [(64)Cu]Cu-DOTA-TOC
por: Vahidfar, Nasim, et al.
Publicado: (2022)

Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues
por: Wolin, Edward M, et al.
Publicado: (2015)

Long-Acting Somatostatin Analogue Safety Monitoring Protocol for Outpatients With Neuroendocrine Tumors
por: Gabrielsen, Jordan, et al.
Publicado: (2019)

Correction: Interaction between somatostatin analogues and targeted therapies in neuroendocrine tumor cells
por: Krug, Sebastian, et al.
Publicado: (2020)

Treatment with somatostatin analogues and PRRT in metastatic middle ear adenoma with neuroendocrine features
por: Lima Ferreira, Joana, et al.
Publicado: (2021)

Initiation of Somatostatin analogues for neuroendocrine tumor patients: a cost-effectiveness analysis
por: Rustgi, Sheila D., et al.
Publicado: (2021)

Chronic Treatment with Somatostatin Analogues in Recurrent Type 1 Gastric Neuroendocrine Tumors
por: Sebastian-Valles, Fernando, et al.
Publicado: (2023)

Molecular and Clinical Implications of Somatostatin Receptor Profile and Somatostatin Analogues Treatment in Oral Cavity Squamous Cell Carcinoma
por: Sanjuan-Sanjuan, Alba, et al.
Publicado: (2021)

Efficacy of octreotide long-acting repeatable in neuroendocrine tumors: RADIANT-2 placebo arm post hoc analysis
por: Strosberg, Jonathan R, et al.
Publicado: (2015)

A Minimal Connected Network of Transcription Factors Regulated in Human Tumors and Its Application to the Quest for Universal Cancer Biomarkers
por: Essaghir, Ahmed, et al.
Publicado: (2012)

Distinct mechanisms of hypoglycaemia in patients with somatostatin‐secreting neuroendocrine tumours
por: Wiesli, Peter, et al.
Publicado: (2019)

Combination treatment with metronomic temozolomide, bevacizumab and long-acting octreotide for malignant neuroendocrine tumours
por: Koumarianou, Anna, et al.
Publicado: (2012)

Somatostatin receptor expression, tumour response, and quality of life in patients with advanced hepatocellular carcinoma treated with long-acting octreotide
por: Cebon, J
Publicado: (2006)

Somatostatin receptor expression, tumour response and quality of life in patients with advanced hepatocellular carcinoma treated with long-acting octreotide
por: Cebon, J, et al.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_mmndt4d0f1n4qm5gs2oa15ksca